Physician profile
David Alan Chalk
NPI 1134106800
$9,580.79
in general payments reported to CMS, 2019-2025
49 companies · $1,768 in 2025
The $1,768 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $734 · 2021: $790 · 2022: $1,629 · 2023: $1,926 · 2024: $1,605 · 2025: $1,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,298 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,298.38 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,435.55 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Melinta Therapeutics, LLC | $1,035.99 | 2019-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Merck Sharp & Dohme LLC | $951.92 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Paratek Pharmaceuticals, INC. | $753.51 | 2020-2025 | Nuzyra |
| Abbvie INC. | $709.90 | 2021-2025 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $647.82 | 2022-2025 | |
| Amgen INC. | $428.41 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.55 | 2019-2025 | Jardiance, Stiolto Respimat |
| Astrazeneca Pharmaceuticals Lp | $413.02 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $410.16 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $375.46 | 2019-2025 | |
| Lilly USA, LLC | $323.56 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $204.47 | 2019-2023 | Xarelto |
| Cumberland Pharmaceuticals, INC. | $169.08 | 2019-2023 | Vibativ |
| Otsuka America Pharmaceutical, INC. | $125.67 | 2022-2023 | Rexulti |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chalk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.